WebBreath Therapeutics’ lead drug candidate, L-CsA-i, is a proprietary liposomal formulation of cyclosporine A for inhalation administered via a drug-specific investigational eFlow® nebulizer (PARI Pharma). L-CsA-i has received orphan drug designation for the treatment of BOS from the Food and Drug Administration and European Medicines Agency. WebJul 11, 2024 · Breath Therapeutics Appoints Noreen Roth Henig, M.D. as Chief Medical Officer The issuer is solely responsible for the content of this announcemen...
Zambon Acquires Breath Therapeutics for Up-to-€500M, …
WebJul 25, 2024 · July 25, 2024. Italian pharma Zambon said today it has acquired Breath Therapeutics and its subsidiaries for up to €500 million (about $559 million), in a deal … WebApplicant: BREATH THERAPEUTICS GMBH Inventors: Martin KNOCH, Oliver DENK Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic … is birmingham v blackburn on tv
Breath Therapeutics Holding BV Spins Out of PARI Pharma With …
WebTopas Therapeutics GmbH. Falkenried 88, Haus A 20251 Hamburg GERMANY +49 40 302089010 [email protected]. CONTACT. CONTACT. CONTACT. Home; About us; Technology; Pipeline; ... She also served as the CFO and Co-Founder of Breath Therapeutics GmbH, where she was instrumental in securing the financing (EUR 43.5 … WebFeb 20, 2024 · February 20, 2024 – Zambon, a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives, and Breath Therapeutics, a Zambon company, specializing in advanced inhaled therapeutics for severe respiratory diseases, announced today the … WebBreath Therapeutics is a spin-out from Munich-based PARI Pharma GmbH and specialises in advanced and first-in-class inhalation therapies for severe respiratory diseases. … is birmingham southern closing